Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
Rhea-AI Summary
Plus Therapeutics (Nasdaq: PSTV) announced that Blue Shield of California will provide reimbursement for the CNSide® CSF Tumor Cell Enumeration assay, effective April 2026, expanding covered lives from ~75 million to ~81 million (+6 million).
The coverage aims to reduce reimbursement barriers, accelerate adoption across oncology centers, and advance the company’s 2026 objective of 150 million covered lives. CNSide reports >11,000 tests since 2020, sensitivity 92%, specificity 95%, and treatment decisions influenced in 90% of cases. Health economic analyses cited ~40% reduction in leptomeningeal metastases-related costs.
AI-generated analysis. Not financial advice.
Positive
- Covered lives +6M (from ~75M to ~81M)
- Tests performed: >11,000 since 2020 at 120+ U.S. cancer centers
- High diagnostic metrics: sensitivity 92% and specificity 95%
- Clinical influence: influenced treatment decisions in 90% of cases
- Cost reduction: health economic analyses estimate ~40% lower LM-related costs
Negative
- Gap to 2026 goal: 81M covered lives vs 150M objective
- Concentration risk: test available exclusively through CNSide Diagnostics service
- Reimbursement variability: coverage still dependent on payer adoption across regions
News Market Reaction – PSTV
On the day this news was published, PSTV declined 0.67%, reflecting a mild negative market reaction. Argus tracked a trough of -11.0% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $275K from the company's valuation, bringing the market cap to $40.83M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PSTV was down 9.24% while only one scanned peer (RNXT) showed momentum, up about 3.44% with no related news, pointing to stock-specific dynamics rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 23 | Manufacturing scale-up | Positive | -4.5% | Added SpectronRx as second GMP site to support late-stage REYOBIQ supply. |
| Apr 22 | Inducement awards | Neutral | -4.5% | Granted stock options and RSUs to new Chief Development Officer under Nasdaq rules. |
| Apr 21 | Nasdaq compliance | Positive | -2.2% | Regained compliance with Nasdaq minimum bid rule after 10 days above $1.00. |
| Apr 15 | Commercial hire | Positive | +4.0% | Appointed VP Value Strategy & HEOR to advance CNSide and REYOBIQ access. |
| Apr 09 | Executive appointment | Positive | +23.7% | Named Eric J. Daniels CDO to drive clinical development of CNS radiotherapeutics. |
Recent news has often been operationally positive, but price reactions have been mixed, with several instances of share weakness following constructive updates.
Over recent weeks, Plus Therapeutics has focused on advancing its CNS pipeline and commercial infrastructure. It added SpectronRx as a second GMP site for REYOBIQ supply, granted inducement awards to its new Chief Development Officer, and regained compliance with Nasdaq’s $1.00 minimum bid rule after a 1-for-25 reverse split. Leadership hires in development and value strategy aim to support CNSide and REYOBIQ execution. Today’s payer coverage expansion for CNSide follows this broader push on manufacturing readiness, market access, and listing compliance.
Market Pulse Summary
This announcement advances Plus Therapeutics’ commercial strategy for CNSide by adding Blue Shield of California, lifting covered lives from about 75 million to 81 million toward a 150 million 2026 goal. The company highlights health economic analyses suggesting a 40% reduction in leptomeningeal metastases-related costs and clinical performance with 92% sensitivity and 95% specificity across more than 11,000 tests. In context of recent manufacturing, regulatory, and leadership milestones, investors may watch further payer additions, real-world adoption and margins for this diagnostic platform.
Key Terms
cerebrospinal fluid medical
assay medical
leptomeningeal metastases medical
clinical utility medical
specificity medical
health economic analyses medical
standard of care medical
AI-generated analysis. Not financial advice.
Expands access by 6 million covered lives, advancing commercial momentum for CNSide® in metastatic CNS cancers
HOUSTON, April 28, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today a new payer coverage agreement with Blue Shield of California, effective April 2026, providing reimbursement for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay for patients with metastatic central nervous system cancers. Blue Shield of California joins a growing list of national and regional payers, including United Healthcare, Humana, and Highmark, that provide coverage for CNSide.
The addition of Blue Shield of California expands CNSide’s total covered lives from approximately 75 million to 81 million, representing continued progress toward the Company’s 2026 objective of 150 million covered lives, while expanding patient access across the U.S. The agreement is expected to further accelerate adoption of CNSide across oncology centers by reducing reimbursement barriers.
“This agreement with Blue Shield of California represents another important step in expanding payer coverage and access to CNSide for patients with leptomeningeal metastases,” said Russ Havranek, EVP Corporate and Commercial Strategy at Plus Therapeutics. “We continue to execute on our strategy to broaden reimbursement, support physician adoption, and improve outcomes for patients with difficult-to-diagnose CNS cancers.”
The CNSide® CSF Assay Platform enables earlier, and more accurate detection and monitoring of leptomeningeal metastases compared to conventional CSF cytology, supporting rapid diagnosis, treatment monitoring, and treatment guidance. The superior clinical utility of CNSide® over standard of care has been demonstrated in nine peer-reviewed publications, the FORESEE clinical trial, and demonstrated in real-world practice. Earlier detection enabled by CNSide has been shown in health economic analyses to reduce overall leptomeningeal metastases-related healthcare costs by ~
Since its commercial launch, more than 11,000 CNSide tests have been performed at over 120 U.S. cancer institutions since 2020, delivering high sensitivity (
This test is available exclusively through CNSide Diagnostics, LLC. as a testing service provided to health care professionals in the U.S.
About CNSide Diagnostics, LLC
CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis of the cerebrospinal fluid that informs and improves the management of patients with leptomeningeal metastases. For more information, visit https://www.cnside-dx.com/.
About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://www.plustherapeutics.com.
About Blue Shield of California
Blue Shield of California strives to create a healthcare system worthy of its family and friends that is sustainably affordable. The health plan is a taxpaying, nonprofit, independent member of the Blue Shield Association with 6 million members, over 6,500 employees and more than
Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.
Investor Contact
CORE IR
investor@plustherapeutics.com
